PMDA (Japan)Pharmaceuticals and Medical Devices Agency

The Pharmaceuticals and Medical Devices Agency (PMDA / 独立行政法人医薬品医療機器総合機構) is an Incorporated Administrative Agency of the Japanese government, operating under the Ministry of Health, Labour and Welfare (MHLW / 厚生労働省). Established 1 April 2004 through the merger of three predecessor bodies, PMDA carries out the scientific assessment work on which MHLW bases its formal regulatory decisions for pharmaceuticals, medical devices, regenerative medical products, in-vitro diagnostics, and cellular / tissue-based products supplied to the Japanese market.

Japan's regulatory framework is the Pharmaceutical and Medical Device Act (PMD Act / 薬機法 — Yakkihō), substantially revised in 2014 (effective 25 November 2014) and amended subsequently including the 2019 cell + gene therapy clarifications and the 2020 UDI + supply-stability provisions. Before 2014 the law was known as the Pharmaceutical Affairs Law (PAL / 薬事法). The PMD Act establishes the marketing authorisation framework, GMP / QMS requirements, post-marketing surveillance obligations, and the MAH (Marketing Authorisation Holder / 製造販売業者) licensing system that is structurally distinctive vs the FDA + EU systems.

PMDA's three core service lines are: (1) review services — scientific assessment of marketing authorisation applications (J-NDA for new drugs, device applications, regenerative medical product applications), (2) safety services — post-marketing safety review, signal management, risk communication, and (3) relief services — compensation for adverse drug reactions + relief for infections contracted from biological products. PMDA also operates the GMP / QMS / GCP / GLP / GPSP inspectorate (since 2005).

PMDA has been a permanent ICH (International Council for Harmonisation) member since 1990 + a PIC/S (Pharmaceutical Inspection Co-operation Scheme) participating authority since 1 July 2014. Japan adopts ICH guidelines into Japanese guidance with minimal adaptation, and PMDA conducts mutual GMP-inspection-recognition activities with selected partners.

Japan's MAH system is structurally distinctive. Under the PMD Act, three separate licences cover the supply chain:

• MAH licence (製造販売業) — the entity legally responsible for placing the product on the Japanese market, holding the marketing authorisation, managing post-marketing safety + quality, and interfacing with PMDA + MHLW. The MAH must be established in Japan and hold a Type 1 MAH licence for prescription drugs (or Type 2 for OTC, or the device-specific equivalents).
• Manufacturing licence (製造業) — for sites manufacturing in Japan; required for each Japan-located manufacturing site.
• Manufacturer accreditation (外国製造業者認定) — for non-Japan manufacturing sites supplying the Japanese market; the foreign manufacturer must obtain accreditation per site per product type.
• Three required personnel under the MAH licence: General Marketing Compliance Officer (総括製造販売責任者), Quality Assurance Officer (品質保証責任者), and Safety Officer (安全管理責任者) — collectively known as 'the three responsible persons' (三役), each with specified Japanese-language + qualification requirements.

For non-Japanese MAHs, two practical routes exist: (1) establish a Japanese subsidiary that holds the MAH licence directly, or (2) use a contracted MAH / Designated Marketing Authorisation Holder (DMAH) arrangement where a Japanese third party formally holds the MAH licence on behalf of the foreign company. Choice has significant strategic + tax + IP implications.

Japanese drug marketing approval involves the J-NDA application (Japanese New Drug Application) following the ICH M4 CTD structure with Japan-specific Module 1 content + Japanese-language requirements.

1. Pre-submission — applicant engages PMDA via the consultation system (相談制度), which has multiple consultation types (clinical pharmacology, exploratory, end-of-Phase-II, pre-NDA, etc.). Consultation is fee-paid + highly recommended.
2. Submission + acceptance — J-NDA submitted in Japanese (Module 1) + English (Modules 2-5 acceptable) to PMDA via the gateway; acceptance triggers the review clock.
3. PMDA review — assigned to a review team with team leader, senior reviewer, and clinical / non-clinical / quality reviewers; team interacts with the applicant throughout via inquiry + response cycles.
4. PAFSC (Pharmaceutical Affairs and Food Sanitation Council) deliberation — the MHLW expert advisory body reviews PMDA's assessment + makes a recommendation; the relevant sub-committee (e.g. Drug Committee No.1 or No.2 depending on indication) leads.
5. MHLW approval — issued under Article 14 of the PMD Act; the formal marketing authorisation that permits market placement.
6. Post-approval re-examination period (再審査) — for new active substances (NMEs), typically 8 years; for orphan drugs up to 10 years; for paediatric indications + cell / gene therapy products with additional protection; the re-examination application is filed by the MAH at the end of the period.
7. Periodic safety update — interim safety reports during the re-examination period + the final re-examination report at the end.
8. Re-evaluation (再評価) — periodic re-assessment of approved products + indications based on accumulated evidence; may result in label change, indication restriction, or withdrawal.

PMDA's published median review time for standard J-NDA review has been ~12 months for several years; Sakigake-designated products + priority reviews can complete in ~9 months. PMDA-FDA-EMA decision-time benchmarking shows Japan typically aligned with EMA + FDA for innovative medicines.

• Class I (低リスク) — General Medical Device; notification (届出) to PMDA; QMS for some sub-categories.
• Class II (中リスク) — Controlled Medical Device; certification (認証) by a Registered Certification Body (RCB / 登録認証機関) against the Japan Industrial Standards (JIS) for the device type; PMDA review only for sub-categories without an RCB-applicable certification standard.
• Class III (高リスク) — Highly Controlled Medical Device; PMDA marketing authorisation (承認) required; full QMS audit.
• Class IV (高リスク, 生命に直接危険を及ぼす) — Highest Risk Medical Device; PMDA marketing authorisation; full QMS audit; typically implantables, life-sustaining, novel high-risk technology.
• Japan QMS Ordinance (MHLW Ordinance No. 169 of 2004, as amended) — substantively aligned with ISO 13485:2016 with Japan-specific MAH-related additions; covers design controls, production controls, CAPA, supplier controls, complaint handling, etc.
• QMS inspection — conducted by PMDA inspectors (or RCBs for Class II); on-site inspections typically required for Class III / IV approvals; remote / hybrid inspection acceptable in some cases.
• AI / SaMD — IDATEN (Improvement Design within Approval for Timely Evaluation and Notice) scheme allows pre-specified post-market software changes under an approved change-control plan, similar in concept to FDA PCCP + EU MDR PCCP.
• UDI — GS1-based barcode labelling required on devices + IVDs per MHLW notifications; phased implementation.

The 2014 PMD Act revision created a new regulatory category specifically for regenerative medical products (再生医療等製品) — distinct from drugs + distinct from devices — with its own review pathway, conditional + time-limited approval framework, and post-marketing surveillance regime. This made Japan the first jurisdiction with a comprehensive conditional + time-limited approval pathway for cell + gene therapy, and continues to attract international sponsors.

• Definition — products consisting of human or animal cells / tissues (or genetically modified cells) used for the treatment of disease, the restoration of function, or the prevention of disease.
• Standard approval — full review based on confirmed efficacy + safety; comparable in standard to drug approval.
• Conditional + time-limited approval (条件及び期限付承認) — when probable efficacy is demonstrated + safety is reasonable, the product may be conditionally approved for up to 7 years; during the period the MAH must collect real-world post-marketing evidence + submit for full approval before expiry. This pathway was the breakthrough that catalysed Japan's regenerative-medicine ecosystem.
• Hospital-based exemption (院内製造) — patient-specific autologous products manufactured + used within a single hospital may operate under the separate Act on Securing Safety in Regenerative Medicine + the Class I / II / III risk classification rather than under PMD Act marketing-authorisation rules.
• PMDA dedicated Regenerative Medical Products Office — specialised review team.
• Foreign data — increasing PMDA acceptance of foreign cell / gene therapy data with appropriate Japanese-context analyses + bridging studies where required.

• Sakigake (先駆け / 先駆) — Pioneer designation; for innovative medicines + devices + regenerative products with significant clinical benefit for serious diseases, targeting Japanese-first or simultaneous-global development. Benefits: prioritised consultations, dedicated PMDA liaison, expedited review (~6-month accelerated clock for medicines vs ~9-12 months standard).
• Priority Review (優先審査) — for products treating serious / life-threatening diseases with significant unmet need; accelerated clock vs standard review.
• Orphan designation (希少疾病用医薬品 / 希少疾病用医療機器 / 希少疾病用再生医療等製品) — for products treating diseases affecting ≤50 000 patients in Japan with significant medical benefit; benefits include fee reductions, priority consultation, extended re-examination period (up to 10 years).
• Conditional Early Approval (条件付き早期承認) — for serious diseases with limited treatment options where conducting a confirmatory study is difficult; pre-Phase-III approval permitted with strict post-marketing data collection.
• Paediatric incentives — extended re-examination period + dedicated review pathway for paediatric extensions.
• Reliance Procedure (since the May 2023 PMDA notification) — selective acceptance of foreign assessment reports + decisions from FDA / EMA / Health Canada / Swissmedic for certain application types, expediting Japanese review.

• Re-examination (再審査) — typically 8 years for new active substances; the MAH collects post-marketing data + submits the re-examination application demonstrating continued benefit-risk acceptability.
• Drug Use Investigation (使用成績調査) — observational study conducted during the re-examination period to monitor real-world safety + effectiveness, often with the J-DSU (Japan Drug Safety Update) data collection.
• Re-evaluation (再評価) — periodic re-assessment of approved products based on accumulated evidence; may be initiated by MHLW for safety signals or by the MAH at re-examination conclusion.
• Risk Management Plan (RMP / 医薬品リスク管理計画) — required for all new drugs since 2013; documents identified + potential risks + pharmacovigilance + risk-minimisation activities.
• Periodic Safety Update Report (PSUR / 安全性定期報告) — periodic safety + benefit-risk update to PMDA; cycle aligned in many cases with global PSUR cycle.
• ICSR reporting (個別症例安全性報告) — adverse-event reporting on E2B(R3) format; serious unexpected ADR reports within 15 days; serious expected ADRs by quarterly periodic report; deaths within 15 days regardless of expectedness.
• Drug Safety Communication (DSC) — MHLW + PMDA safety alerts published via Drug Safety Update + Healthcare Professional Letters (HCP).
• Medical Device Adverse Event Reporting — manufacturer + RCB reporting via PMDA's submission gateway; serious incident timelines aligned in substance with FDA MDR + EU MDR Article 87.

• MAH triage gaps — Japanese subsidiary / DMAH structure not properly established; Three Responsible Persons (三役) not in place or not qualified.
• Japanese-language Module 1 errors — administrative documents, package insert (添付文書), labelling not aligned with PMDA expectations; translation quality issues delaying review.
• Consultation history not properly leveraged — applicant deviates from consultation outcomes without justifying the change.
• Bridging study expectations underestimated — Japanese-specific clinical data requirements not met; PK / PD / dose-response differences not addressed.
• Sakigake commitments not fulfilled — pre-marketing development milestones missed, threatening designation status.
• GMP inspection critical findings — data integrity, computerised systems (Annex 11 / J-GMP equivalent), aseptic processing (per the 2024 PIC/S Annex 1 alignment), supplier-control gaps.
• QMS Ordinance audit findings — Japan-specific MAH-related controls inadequate; supplier controls weak; CAPA effectiveness verification missing.
• Foreign manufacturer accreditation gap — site supplying the Japanese market without accreditation; product seizure + market action.
• Re-examination data collection inadequate — Drug Use Investigation methodology weak; sample size insufficient; data quality concerns.
• PSUR / safety reporting timeline missed — 15-day SUSAR reporting late; signal-detection cycle slow.
• Risk Management Plan additional risk-minimisation measures (aRMM) not implemented or ineffective — Japan-specific educational materials, patient cards, controlled distribution.
• Device QMS Class III / IV inspection findings — design controls per JIS T 14971 (the Japanese adoption of ISO 14971) weak; software per IEC 62304 documentation thin.
• IDATEN scheme misapplication — pre-specified change protocol scope too broad; PMDA reverts the change to a formal change application.
• Regenerative medical product conditional approval — post-marketing real-world evidence collection programme insufficient; risk of conditional-approval expiry without conversion to full approval.
• Reliance Procedure misalignment — applicant assumes Reliance acceptance for a category not yet covered; full review re-triggered.

• Consultation count + outcome-incorporation rate before submission.
• J-NDA acceptance-rate at first submission.
• Inquiry-cycle count + response cycle time.
• Time-from-acceptance-to-MHLW-approval (calendar months) — typically 12 months standard, 9 months priority / Sakigake.
• Re-examination period progress; Drug Use Investigation enrolment vs plan.
• PSUR + ICSR on-time submission rate to PMDA.
• Sakigake designation count + on-time milestone delivery.
• GMP / QMS inspection outcomes (Critical / Major / Minor counts).
• Foreign manufacturer accreditation continuity per Japan-supplying site.
• Risk Management Plan aRMM implementation + effectiveness.
• Device IDATEN utilisation — pre-approved change count + scope conformance.
• Regenerative medical product conditional approval — post-marketing data milestone delivery + full-approval conversion timeline.
• Reliance Procedure utilisation rate + first-time acceptance.

V5 Ultimate runs the GMP + QMS + pharmacovigilance evidence layer that sits beneath every PMDA-supervised activity. Specifically:

• Japan GMP + Annex 11 equivalent control framework — computerised-systems lifecycle, electronic-record + electronic-signature controls aligned with the PIC/S + ICH expectations PMDA enforces.
• MAH workflow — Three Responsible Persons sign-off routing (General Marketing Compliance Officer / Quality Assurance Officer / Safety Officer) on batch release + product-quality decisions + safety reporting.
• J-NDA dossier preparation — eCTD with Japan-specific Module 1 staging, Japanese package insert (添付文書) authoring, bilingual artefact management for Modules 2-5.
• Consultation history log — every PMDA consultation captured with commitments tracked + incorporated.
• Re-examination + re-evaluation cycle calendar — milestone tracking, Drug Use Investigation enrolment + data-collection programme, re-examination application preparation.
• Risk Management Plan + additional risk-minimisation measures — Japan-specific implementation including HCP letters, patient materials, controlled distribution.
• PSUR + ICSR pipeline — E2B(R3) ICSR submission to PMDA gateway on the 15-day / quarterly / periodic timelines; PSUR cycle aligned with global cycle where appropriate.
• QMS Ordinance compliance for Class III / IV devices — design controls, production controls, CAPA, supplier controls aligned with the Japan QMS Ordinance + ISO 13485:2016 baseline; JIS T 14971 risk-management file.
• IDATEN / PCCP support — change-control routing engine handles pre-approved change protocols within scope + escalates out-of-scope changes to a formal application.
• Foreign manufacturer accreditation tracking — per-site, per-product-type accreditation status with renewal calendar.
• Reliance Procedure submission — for eligible products, automated assembly of FDA / EMA / Health Canada / Swissmedic reference assessment reports + Japan-specific bridging rationale.
• GMP / QMS inspection readiness — site master file, validation master plan, deviation + CAPA log, change-control log, PQR / APQR cycle, training records aligned with Japanese GMP guidance + PIC/S Annex 1 (2022).